Findings

What do systematic reviews say?

77 questions · 77 findings · 27 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 44 · 57.1%GRADE not reported 1 · 1.3%Very low 6 · 7.8%Low 16 · 20.8%Moderate 8 · 10.4%High 2 · 2.6%

Laser ablation vs radiofrequency ablation

Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

The review found no eligible studies for this question.

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation

Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

The review found no eligible studies for this question.

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Transarterial embolisation plus percutaneous alcohol injection vs percutaneous alcohol injection

Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

The review found no eligible studies for this question.

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Surgery vs radiofrequency ablation

Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery

The review found no eligible studies for this question.

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life · ethnic minority groups with type 2 diabetes mellitus

1 finding from 1 review

Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 224 participants
Low

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)

Health‐related quality of life6 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sorafenib vs sunitinib (targeted agent versus targeted agent)

Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Everolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Systemic antifungal vs placebo/no treatment

Generic quality of life measures · chronic rhinosinusitis

The review found no eligible studies for this question.

1 finding from 1 review

Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 38 participants
Very low

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Low

Pazopanib vs sunitinib (targeted agent versus targeted agent)

Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 467 participants
Low

Silicone gel sheeting vs intralesional injections of triamcinolone acetonide

Health‐related quality of life · people with keloid scars

The review found no eligible studies for this question.

1 finding from 1 review

Silicone gel sheeting for treating keloid scars 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low